Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial

Lancet

Volumn 360, Issue 9350, 2002, Pages 2001-2008

  Cherry, Nicola ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE; ESTROGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; FEMALE; FRACTURE; HEART DEATH; HEART INFARCTION; HEART REINFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL; UNITED KINGDOM; UTERUS BLEEDING;

EID: 0037153707     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)12001-0     Document Type: Article

References (31)

1. Barratt-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Public Health. 19:1998;55-72.
2. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:1995;199-208.
3. Espeland M.A., Marcovina S.M., Miller V., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 97:1998;979-986.
4. Mendelsohn M.E., Karas R.H. Protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811.
5. Meilahn E.N., Kuller L.H., Matthews K.A., Kiss J.E. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 2:1992;445-455.
6. Sporrong T., Mattsson L.A., Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progesterone treatment of postmenopausal women. Br J Obstet Gynaecol. 97:1990;939-944.
7. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., Melis G.B. Effects of low doses of transdermal 17beta-oestradiol on carbohydrate metabolism in post menopausal women. J Clin Endocrinol Metab. 74:1992;1396-1400.
8. Gotto A.M. Jr. Triglycerides: the forgotten risk factor. Circulation. 97:1998;1027-1028.
9. Hamsten A. Coagulation factors and hyperlipidaemia. Curr Opin Lipidol. 2:1991;266-271.
10. Sullivan J.M., Swaag R.V., Hughes J.P., et al. Estrogen replacement and coronary artery disease: effects of survival in post menopausal women. Arch Intern Med. 150:1990;2557-2562.
11. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 343:2000;522-529.
12. Angerer P., Störk S., Kothny W., Schmitt P., von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 21:2001;262-268.
13. Angerer P., Störk S., Kothny W., von Schacky C. Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. Maturitas. 41:2001;51-60.
14. Waters D.D., Alderman E.L., Hsia J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 288:2002;2432-2440.
15. Hodis H.N., Mack W.J., Lobo R.A., et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 135:2001;939-953.
16. Schulman S.P., Thiemann D.R., Ouyang P., et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol. 39:2002;231-237.
17. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
18. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6·8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 288:2002;49-57.
19. Clarke S.C., Kelleher J., Lloyd-Jones H., Slack M., Schofiel P.M. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol. 109:2002;1056-1062.
20. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 345:2001;1243-1249.
21. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
22. Fletcher S.W., Colditz G.A. Failure of estrogen plus progestin therapy for prevention. JAMA. 288:2002;366-368.
23. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360:2002;942-944.
24. Heckbert S.R., Kaplan R.C., Weiss N.S., et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med. 161:2001;1709-1713.
25. Alexander K.P., Newby K., Hellkamp A.S., et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol. 38:2001;1-7.
26. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med. 135:2001;1-8.
27. Meade T.W., Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull. 48:1992;276-308.
28. Kay C.R. Progestogens and arterial disease: evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol. 142:1982;762-765.
29. Henderson B.E., Ross R.K., Lobo R.A., Pike M.C., Meek J.M. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 49:(suppl 2):1988;9S-15.
30. Daly E., Roach M., Barlow D., et al. HRT: an analysis of benefits, risks and costs. Br Med Bull. 48:1992;368-400.
31. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.